- Article
CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML
- Belinda S. Schmalzbauer,
- Teresemary Thondanpallil,
- Gerwin Heller,
- Alessia Schirripa,
- Clio-Melina Sperl,
- Isabella M. Mayer,
- Vanessa M. Knab,
- Sofie Nebenfuehr,
- Markus Zojer and
- Karoline Kollmann
- + 4 authors
Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by...